HSV2 vaccine (G103) / Merck (MSD), Sanofi - LARVOL DELTA

Safety and immunogenicity of investigational herpes simplex virus-2 vaccines in adults with recurrent genital infection. (PubMed, Vaccine) - "gD2, UL19, and UL25-specific CD4 T cells increased in G103 recipients after the first dose and were most robust for gD2. Binding antibody levels increased most markedly for UL25, as did neutralizing antibodies."

Clinical • Journal • Herpes Simplex • Infectious Disease • Musculoskeletal Pain • Pain • CD4

Nonclinical safety evaluation of two vaccine candidates for Herpes Simplex Virus type 2 to support combined administration in humans. (PubMed, J Appl Toxicol) - "Three repeated-dose toxicity studies, one in guinea pigs and two in rabbits, were conducted to assess systemic toxicity and local tolerance of HSV529, alone or adjuvanted with GLA-SE, or G103 containing GLA-SE. Data from these studies show that both vaccines are safe and well tolerated and support the ongoing HSV-2 clinical trial in which the two vaccine candidates will be given either sequentially or concomitantly to explore their potential synergistic and incremental effects."

Journal • CNS Disorders • Herpes Simplex • Human Immunodeficiency Virus • Infectious Disease